Skip to content
    Reviews

    HIPEC in Advanced Epithelial Ovarian Cancer: Clinical Evidence, Patient Selection, and Toxicity

    AlAshqar et alCurrent Obstetrics and Gynecology Reports

    HIPEC in Advanced Epithelial Ovarian Cancer: Clinical Evidence, Patient Selection, and Toxicity
    Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) is an adjunct locoregional modality for advanced epithelial ovarian cancer that utilizes enhanced intraperitoneal drug delivery alongside the cytotoxic effects of hyperthermia.
    According to this review, the strongest clinical evidence supports HIPEC during interval cytoreductive surgery following neoadjuvant chemotherapy, with randomized trials demonstrating improvements in both progression-free survival and overall survival without causing long-term harm to patient quality of life. Conversely, the evidence for HIPEC during primary CRS or in the recurrent disease setting remains mixed, with outcomes contingent on patient selection and specific disease contexts.
    Crucial determinants of patient outcomes include the completeness of cytoreduction, overall disease burden, performance status, and patient frailty; chronological age alone does not constitute a contraindication. While HIPEC increases perioperative morbidity—specifically elevating the risk of nephrotoxicity, electrolyte disturbances, and hematologic complications—these toxicities are manageable in experienced centers and do not delay the initiation of subsequent adjuvant therapy. Additionally, emerging evidence suggests biomarkers including homologous recombination deficiency (HRD) status and CA-125 KELIM scores may further optimize patient selection, as ongoing trials evaluate how best to integrate HIPEC with modern maintenance therapies.

    Key Takeaways

    • Randomized trials demonstrate improvements in progression-free and overall survival without long-term detriment to quality of life when hyperthermic intraperitoneal chemotherapy is administered at the time of interval cytoreductive surgery following neoadjuvant chemotherapy.
    • Evidence supporting hyperthermic intraperitoneal chemotherapy during primary cytoreductive surgery or in recurrent ovarian cancer remains mixed, with clinical benefits heavily dependent on disease context and patient selection.
    • Hyperthermic intraperitoneal chemotherapy is associated with increased perioperative morbidity, notably nephrotoxicity, electrolyte disturbances, and hematologic complications, though these risks remain manageable at experienced centers and do not delay adjuvant therapy.
    Read the original sourceCurrent Obstetrics and Gynecology Reports